FDA testimony proved sales won't be robust even if approved .....
LMAO on opening stock price guess of $5.00 by some total lemming who just can't wait to sell when the bell rings. FDA doctors clearly said that doctors won't be rushing to presribe the treatment. Opening price ? I'll say $1.75
I think sales will be better than anyone suspects.
The FDA testimony didn't PROVE anything. The dosing discussion has merit from the point of looking for the perfect medication for each individual. But from the trenches of dealing with addicts in the field ... clinicians are not grasping for perfection ... they are looking for something that will help. And that help is probuphine. Look at the graphic in the presentation that showed that the pb users required immensely less supplemental suboxone than the suboxone group. This is why anyone that has trouble maintaining the schedule of taking their medication each and every day (likely most addicts) will try it and benefit from it.
The view of the addiction problem is very different from the trenches than it is in the halls of the FDA..
It is difficult for rationale well-adjusted comfortable people to fully appreciate the agonies and desperation of the addict.